Market closed
Regeneron/$REGN
Regeneron shares are trading higher after receiving a buy rating, highlighting its strong drug pipeline, profit margins, and low debt levels.
9 hours ago·Lightyear AI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Regeneron
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
Ticker
$REGN
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
15,158
ISIN
US75886F1075
Website
Regeneron Metrics
BasicAdvanced
$56B
13.39
$39.43
0.43
$0.88
0.67%
Price and volume
Market cap
$56B
Beta
0.43
52-week high
$1,206.81
52-week low
$520.50
Average daily volume
1.3M
Dividend rate
$0.88
Financial strength
Current ratio
5.708
Quick ratio
3.9
Long term debt to equity
9.204
Total debt to equity
9.204
Dividend payout ratio (TTM)
2.08%
Interest coverage (TTM)
82.68%
Management effectiveness
Return on assets (TTM)
6.87%
Return on equity (TTM)
15.96%
Valuation
Price to earnings (TTM)
13.386
Price to revenue (TTM)
4.033
Price to book
1.9
Price to tangible book (TTM)
1.98
Price to free cash flow (TTM)
19.178
Dividend yield (TTM)
0.17%
Forward dividend yield
0.67%
Growth
Revenue change (TTM)
7.52%
Earnings per share change (TTM)
16.49%
3-year revenue growth (CAGR)
-5.15%
3-year earnings per share growth (CAGR)
-17.53%
What the Analysts think about Regeneron
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Regeneron stock.
Regeneron Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Regeneron Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Regeneron News
AllArticlesVideos
Regeneron Continues To Regenerate Its Drug Pipeline, While Keeping Leverage Down
Seeking Alpha·13 hours ago
Trump Declares War On Pharma Drug Pricing, But The Stocks Aren't Tanking - Yet
Seeking Alpha·13 hours ago
Regeneron to Highlight Advances at ASCO with Phase 3 Adjuvant Libtayo® (cemiplimab) CSCC Updates and Promising Early Blood Cancer Data with Linvoseltamab Combination
GlobeNewsWire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Market closed
Upcoming events
May20
Regeneron
Dividend·Ex-dividend
Jun6
Regeneron
Dividend·Payment
$0.88Per share
FAQs
What’s the current market cap for Regeneron stock?
Regeneron (REGN) has a market cap of $56B as of May 13, 2025.
What is the P/E ratio for Regeneron stock?
The price to earnings (P/E) ratio for Regeneron (REGN) stock is 13.39 as of May 13, 2025.
Does Regeneron stock pay dividends?
Yes, the Regeneron (REGN) stock pays dividends to shareholders. As of May 13, 2025, the dividend rate is $0.88 and the yield is 0.67%. Regeneron has a payout ratio of 2.08% on a trailing twelve-month basis.
When is the next Regeneron dividend payment date?
The next Regeneron (REGN) dividend payment is scheduled for June 06, 2025.
What is the beta indicator for Regeneron?
Regeneron (REGN) has a beta rating of 0.43. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.